Seeking Alpha

SVNT
Savient Pharmaceuticals Inc

5/23/2012, 9:46 AM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SVNT Market Currents more »
  • May 9 Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates. Total revenue actually jumped nearly 170% Y/Y, but bottom line margins were hit as expenses increased sharply. Much of the increase in expenses had to do with the commercialization and marketing of its new gout drug Krystexxa.
    Comment!
    [Healthcare, Earnings, On the Move]
SVNT in Focus more »
SVNT News more »
SVNT Instablog posts more »
  • Investment Report - March 2012: Opportunistic Levered
    Mon, Mar 12 • Stone Fox Capital • Comment!
  • Savient Pharma Gets Permanent J-Code For KRYSTEXXA
    Fri, Jan 6 • Stone Fox Capital • Comment!
  • Savient Pharmaceuticals Moves to a Top-Tier Auditor
    Mon, Dec 5, 2011 • Disclosure Insight • Comment!
  • Stock World Weekly: Euro Fever
    Mon, May 30, 2011 • Philip Davis • Comment!
  • Stock World Weekly: Euro Fevor
    Mon, May 30, 2011 • Ilene at PSW • Comment!
Write a post on SVNT
SVNT StockTalks
SVNT vs. ETF Alternatives
Company Description

We are a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase), or KRYSTEXXA, for the treatment of chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize... More

Sector: Healthcare
Industry: Biotechnology
Country: United States